Akt/mTOR
GBP5
autophagy
chemotherapy
taxane
triple-negative breast cancer
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
12 Mar 2021
12 Mar 2021
Historique:
received:
10
02
2021
revised:
08
03
2021
accepted:
09
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Pre-operative (neoadjuvant) or post-operative (adjuvant) taxane-based chemotherapy is still commonly used to treat patients with triple-negative breast cancer (TNBC). However, there are still no effective biomarkers used to predict the responsiveness and efficacy of taxane-based chemotherapy in TNBC patients. Here we find that guanylate-binding protein 5 (GBP5), compared to other GBPs, exhibits the strongest prognostic significance in predicting TNBC recurrence and progression. Whereas GBP5 upregulation showed no prognostic significance in non-TNBC patients, a higher GBP5 level predicted a favorable recurrence and progression-free condition in the TNBC cohort. Moreover, we found that GBP5 expression negatively correlated with the 50% inhibitory concentration (IC
Identifiants
pubmed: 33809079
pii: jpm11030197
doi: 10.3390/jpm11030197
pmc: PMC8001168
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 108-2320-B-038-017-MY3
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 109-2314-B-038-078-MY3
Références
mBio. 2018 Aug 28;9(4):
pubmed: 30154263
Small GTPases. 2017 Jan 2;8(1):31-37
pubmed: 27275775
Ann Oncol. 2014 Mar;25(3):611-618
pubmed: 24401929
Lancet. 2002 Sep 28;360(9338):1007-14
pubmed: 12383682
Int J Clin Exp Pathol. 2012;5(8):806-13
pubmed: 23071863
Autoimmun Rev. 2021 Feb;20(2):102741
pubmed: 33340772
J Virol. 2020 Oct 14;94(21):
pubmed: 32796072
J Natl Cancer Inst. 2018 Jun 1;110(6):628-637
pubmed: 29228315
Nature. 2019 Aug;572(7770):538-542
pubmed: 31367040
Front Oncol. 2020 Jan 10;9:1494
pubmed: 31998647
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Am Soc Clin Oncol Educ Book. 2015;:e25-30
pubmed: 25993181
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Clin Med Insights Oncol. 2016 Apr 05;10(Suppl 1):31-9
pubmed: 27081325
BMC Cancer. 2017 Nov 7;17(1):727
pubmed: 29115931
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
BMC Genomics. 2015 May 28;16:412
pubmed: 26016888
Cancer Manag Res. 2018 Jan 15;10:91-103
pubmed: 29391830
Mol Cells. 2019 Sep 30;42(9):628-636
pubmed: 31564074
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
J Interferon Cytokine Res. 2007 Jan;27(1):44-52
pubmed: 17266443
Ann Oncol. 2019 Jul 1;30(7):1051-1060
pubmed: 31050709
Ann Oncol. 2015 Mar;26(3):523-8
pubmed: 25480878
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Cancer Treat Rev. 2016 Apr;45:87-96
pubmed: 26995633
Acta Neuropathol. 2018 Apr;135(4):581-599
pubmed: 29350274
J Cell Mol Med. 2020 Dec;24(24):14525-14538
pubmed: 33159487
PLoS One. 2014 Jun 04;9(6):e98370
pubmed: 24896091
Genet Mol Biol. 2020 Nov 17;43(4):e20190230
pubmed: 33211060
Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):1365-1370
pubmed: 28123064
Drug Discov Today. 2019 Nov;24(11):2181-2191
pubmed: 31520748
Oncoimmunology. 2018 Feb 1;7(5):e1423170
pubmed: 29721376
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
J Innate Immun. 2017;9(4):419-435
pubmed: 28376501
Science. 2012 Apr 27;336(6080):481-5
pubmed: 22461501
Cancers (Basel). 2020 Jul 31;12(8):
pubmed: 32751846
Breast Cancer. 2014 Jul;21(4):491-9
pubmed: 23001506
Am J Clin Pathol. 2014 Apr;141(4):462-77
pubmed: 24619745
Int J Biol Markers. 2010 Apr-Jun;25(2):104-11
pubmed: 20544688
Clin Cancer Res. 2013 Jan 1;19(1):28-33
pubmed: 23258741
Nat Commun. 2019 Sep 26;10(1):4375
pubmed: 31558756
Int J Oncol. 2020 Sep;57(3):858-870
pubmed: 32582960